ReNeuron Group plc is a UK-based clinical-stage biotechnology company specializing in the development and commercialization of novel cell and gene therapies for serious unmet medical needs. Founded in 1997 as a spin-out from Cambridge University, the company has built a proprietary platform centered on human neural stem cells and exosome-based technologies. Its core mission is to harness the regenerative potential of these cells and their secreted vesicles to address conditions affecting the central nervous system and sensory organs.
The company’s most advanced program, CTX, uses neural stem cells to target disability arising from stroke. Following successful Phase I and IIa clinical trials, ReNeuron is evaluating CTX in larger-scale studies aimed at demonstrating functional recovery in stroke survivors. Alongside CTX, the company is developing its PNT-200 series of progenitor cells for retinal disorders such as retinitis pigmentosa. Preclinical data suggest that these cells may help preserve or restore visual function by replacing or supporting damaged photoreceptors in the eye.
In addition to cell therapies, ReNeuron’s exosome platform offers a versatile approach for delivering therapeutic payloads across the blood-brain and blood-retinal barriers. By engineering exosomes derived from its proprietary cell lines, the company aims to create off-the-shelf products capable of carrying nucleic acids, proteins or small molecules to target tissues. This dual focus on stem cells and exosomes positions ReNeuron to address a broad range of neurological and ocular diseases with high unmet need.
Headquartered in Nottingham, England, ReNeuron conducts research and manufacturing at facilities in the UK and collaborates with academic institutions and commercial partners worldwide. Under the leadership of Chief Executive Officer Martin McGlynn and a board of directors with extensive experience in biotechnology and clinical development, the company is advancing multiple programs toward late-stage trials and potential commercialization.
AI Generated. May Contain Errors.
